These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 10528911)

  • 21. The microenvironment in mature B-cell malignancies: a target for new treatment strategies.
    Burger JA; Ghia P; Rosenwald A; Caligaris-Cappio F
    Blood; 2009 Oct; 114(16):3367-75. PubMed ID: 19636060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A summer of change in hematologic malignancies: highlights in B-Cell malignancies from the 2013 ASCO, EHA, and ICML meetings.
    Cheson BD
    Clin Adv Hematol Oncol; 2013 Nov; 11(11):748-50. PubMed ID: 24896550
    [No Abstract]   [Full Text] [Related]  

  • 23. Hematology in 2010: New therapies and standard of care in oncology.
    DeVita VT; Canellos GP
    Nat Rev Clin Oncol; 2011 Feb; 8(2):67-8. PubMed ID: 21278770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurologic complications of antitumor antibody therapies.
    Kreisl TN
    Curr Neurol Neurosci Rep; 2008 May; 8(3):259-63. PubMed ID: 18541121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor upregulation enhances cell surface receptor targeted therapies.
    Frankel AE
    Leuk Res; 2002 Dec; 26(12):1069-71. PubMed ID: 12443877
    [No Abstract]   [Full Text] [Related]  

  • 26. Introduction: emerging therapies for hematologic malignancies: antibodies, antisense, and cytokine approaches.
    Appelbaum FR
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):1. PubMed ID: 10530709
    [No Abstract]   [Full Text] [Related]  

  • 27. Emerging role of target-based therapies for gastrointestinal malignancies.
    Dragovich T
    J BUON; 2005; 10(1):15-21. PubMed ID: 17335127
    [No Abstract]   [Full Text] [Related]  

  • 28. A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection.
    Hychko G; Mirhosseini A; Parhizgar A; Ghahramani N
    Int J Organ Transplant Med; 2011; 2(2):51-6. PubMed ID: 25013595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alemtuzumab.
    Frampton JE; Wagstaff AJ
    Drugs; 2003; 63(12):1229-43; discussion 1245-6. PubMed ID: 12790693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
    Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
    Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients.
    Ladetto M; Bergui L; Ricca I; Campana S; Pileri A; Tarella C
    Med Oncol; 2000 Aug; 17(3):203-10. PubMed ID: 10962531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future strategies toward the cure of indolent B-cell malignancies: introduction.
    Cheson BD
    Semin Hematol; 1999 Oct; 36(4 Suppl 5):1-2. PubMed ID: 10528908
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
    Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
    Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
    Bosly A; Keating MJ; Stasi R; Bradstock K
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Future strategies toward the cure of indolent B-cell malignancies. New biologic therapies.
    Rai KR
    Semin Hematol; 1999 Oct; 36(4 Suppl 5):12-7. PubMed ID: 10528911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future strategies toward the cure of indolent B-cell malignancies. Immune recognition and antiself.
    Nadler LM
    Semin Hematol; 1999 Oct; 36(4 Suppl 5):9-11. PubMed ID: 10528910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches.
    Kipps TJ
    Semin Hematol; 1999 Oct; 36(4 Suppl 5):3-8. PubMed ID: 10528909
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.